Biography for Eric Palmer
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family.
Articles by Eric Palmer
Federal agents reportedly carried boxes of documents out of the Reckitt Benckiser headquarters in Virginia on Tuesday. The officials did not disclose the purpose of the warrant.
AstraZeneca has gotten EU approval for its inhaled, four-in-one vaccine for children. Fluenz Tetra is among a new generation of treatments that are expected to carry premium prices and so boost the revenues companies will generate from a part of the market once considered a backwater.
Robert Wessman, the Icelandic entrepreneur who built Actavis into a generics powerhouse and then sold out, has decided get into the biosimilars business. He has talked his home country into helping finance his plans.
Pfizer says it will support the trend toward making more data from clinical trials available by providing easy-to-understand summaries to patients who participate in the independent studies.
A Jubilant Life Sciences plant has joined a growing list of Indian drugmakers' facilities that have gotten crosswise with the FDA lately. But this time it is for a plant in the U.S., the second Jubilant plant in North America tagged by the agency this year.
Pfizer has always been proud of its design of Viagra, which has become known worldwide for its blue color and diamond shape. It thinks enough of it that it is fighting a pitched legal battle in Korea with drugmaker Hanmi Pharmaceutical over the shape of Hanmi's generic, which has grabbed nearly half the market there.
After settling much of the litigation tied to the health effects on newborns whose mothers took the antidepressant Paxil during pregnancy, maker GlaxoSmithKline has now won a wrongful death case brought by a woman who said she aborted after she was told her fetus had congenital heart defects.
Mylan's buyout of Agila Specialties from India's Strides Arcolab hit a hitch after the FDA issued a warning letter to one of Agila's plants. Mylan said it was holding back $250 million of the $1.75 billion payout until the regulatory issues get resolved.
U.K. Prime Minister David Cameron thinks GlaxoSmithKline is a "very decent and strong British business" and has been talking it up with Chinese officials during his trade visit there.
Pfizer is shedding 150 employees at its facility in Newbridge, Ireland. The company says the cuts are needed as generic competition continues to eat away at its revenues. The move comes just two weeks after the U.S. drugmaker targeted a plant in Puerto Rico for closure.